ILO ELMAR LEPPIK, M.D.
Neurology at Wayzata Blvd, Minneapolis, MN
License number
Minnesota 22617
Category
Neurology
Type
Neurology
License number
Minnesota 16819-020
Category
Neurology
Type
Neurology
Address
Address
5775 Wayzata Blvd STE 200, Minneapolis, MN 55416
Phone
(952) 525-4511
(952) 525-1560 (Fax)
(952) 525-1560 (Fax)
Personal information
See more information about ILO ELMAR LEPPIK at radaris.comName
Address
Phone
Golden Valley, MN
7500 Western Ave, Golden Valley, MN 55427
Professional information
Dr. Ilo E Leppik, Minneapolis MN - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
Mincep Epilepsy Care
5775 Wayzata Blvd SUITE 200, Minneapolis 55416
(952) 525-2400 (Phone)
5775 Wayzata Blvd SUITE 200, Minneapolis 55416
(952) 525-2400 (Phone)
Certifications:
Neurology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Mincep Epilepsy Care
5775 Wayzata Blvd SUITE 200, Minneapolis 55416
Abbott Northwestern Hospital
800 East 28Th St, Minneapolis 55407
5775 Wayzata Blvd SUITE 200, Minneapolis 55416
Abbott Northwestern Hospital
800 East 28Th St, Minneapolis 55407
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1968
Wisconsin
Montreal Neur Inst
Perelman School of Medicine University of Pennsylvania
Graduated: 1968
Wisconsin
Montreal Neur Inst
Ilo Elmar Leppik, St Louis Park MN
Specialties:
Neurologist
Address:
5775 Wayzata Blvd, St Louis Park, MN 55416
Education:
University of Pennsylvania, Perelman School of Medicine - Doctor of Medicine
McGill University Health Centre-Montreal Neurological Hospital - Fellowship - Epilepsy
McGill University Health Centre-Montreal Neurological Hospital - Fellowship - Epilepsy
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Ilo Elmar Leppik, Minneapolis MN
Specialties:
Neurology
Work:
Mincep Epilepsy Care
5775 Wayzata Blvd, Minneapolis, MN 55416
5775 Wayzata Blvd, Minneapolis, MN 55416
Education:
University of Pennsylvania(1968)
Novel Parenteral Carbamazepine Formulation
US Patent:
2007018, Aug 9, 2007
Filed:
Oct 2, 2006
Appl. No.:
11/542520
Inventors:
James Cloyd - Edina MN, US
Angela Birnbaum - Minneapolis MN, US
Ilo Leppik - Minneapolis MN, US
Stephen Collins - Lake Forest IL, US
Angela Birnbaum - Minneapolis MN, US
Ilo Leppik - Minneapolis MN, US
Stephen Collins - Lake Forest IL, US
International Classification:
A61K 31/724, C08B 30/18, C08B 37/16
US Classification:
514058000, 514217000, 536046000
Abstract:
The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.
Novel Parenteral Carbamazepine Formulation
US Patent:
2010020, Aug 12, 2010
Filed:
Sep 30, 2009
Appl. No.:
12/571039
Inventors:
James Cloyd - Edina MN, US
Angela Birnbaum - Minneapolis MN, US
Ilo Leppik - Minneapolis MN, US
Stephen D. Collins - Lake Forest IL, US
Angela Birnbaum - Minneapolis MN, US
Ilo Leppik - Minneapolis MN, US
Stephen D. Collins - Lake Forest IL, US
International Classification:
A61K 31/724, C08B 37/16, A61P 25/08
US Classification:
514 58, 5361231, 536124
Abstract:
The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.
Novel Parenteral Carbamazepine Formulation
US Patent:
2013007, Mar 21, 2013
Filed:
Nov 16, 2012
Appl. No.:
13/679715
Inventors:
H. Lundbeck LLC - Deerfield IL, US
Angela BIRNBAUM - Minneapolis MN, US
Ilo LEPPIK - Minneapolis MN, US
Stephen D. COLLINS - Lake Forest IL, US
Angela BIRNBAUM - Minneapolis MN, US
Ilo LEPPIK - Minneapolis MN, US
Stephen D. COLLINS - Lake Forest IL, US
Assignee:
H. LUNDBECK LLC - Deerfield IL
International Classification:
A61K 31/55, A61K 47/40
US Classification:
514217
Abstract:
The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.
Novel Parenteral Carbamazepine Formulation
US Patent:
2014008, Mar 20, 2014
Filed:
Oct 11, 2013
Appl. No.:
14/051938
Inventors:
Angela BIRNBAUM - Minneapolis MN, US
Ilo LEPPIK - Minneapolis MN, US
Stephen D. COLLINS - Lake Forest IL, US
Ilo LEPPIK - Minneapolis MN, US
Stephen D. COLLINS - Lake Forest IL, US
Assignee:
LUNDBECK LLC - Deerfield IL
International Classification:
A61K 47/40, A61K 9/00, A61K 31/55
US Classification:
514217
Abstract:
The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.